Scientists from the Gothenburg and Girona universities found that the treatment of type 2 diabetes with metformin is changing the composition and characteristics of the intestinal microbiome. This has a significant auxiliary effect in therapy, establishing a system of regulation of the level of sugar and glycosylated hemoglobin in the blood.